Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Schmid

Showing results (411-420 of 629) with videos related to

Pageof 63
Sort By:
Dermatitis : Contact, Atopic, Occupational, Drug|February 1, 2023
The Association Between Fatigue and Adult Atopic Dermatitis: A Cross-Sectional StudyJacob P Thyssen, Lea K Nymand, Julia-Tatjana Maul, et al.
The Journal of Allergy and Clinical Immunology|January 8, 2011
TNF-like weak inducer of apoptosis (TWEAK) and TNF-α cooperate in the induction of keratinocyte apoptosisMaya Zimmermann, Andrea Koreck, Norbert Meyer, et al.
BJU International|November 22, 2017
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavirDominik Abt, Andrej Besse, Lenka Sedlarikova, et al.
Hepatology (Baltimore, Md.)|August 8, 2014
Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modelingJeremie Guedj, Yaron Rotman, Scott J Cotler, et al.
The Journal of Dermatological Treatment|February 12, 2016
Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndromeAstrid Sönnichsen, Ieva Saulite, Johanna Mangana, et al.
Future Oncology (London, England)|April 1, 2020
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancerHope S Rugo, Aditya Bardia, Sara M Tolaney, et al.
Cancer Research|March 16, 2011
Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancerNelofer Syed, Helen M Coley, Jalid Sehouli, et al.
Cancer Immunology, Immunotherapy : CII|April 14, 2006
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinomaYing Waeckerle-Men, Edith Uetz-von Allmen, Markus Fopp, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 30, 2025
PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [<sup>68</sup>Ga]Ga-PSMA-11, [<sup>68</sup>Ga]Ga-PSMA I&T, and [<sup>18</sup>F]PSMA-1007Caroline Burgard, Madita Frei, Arne Blickle, et al.
Clinical Chemistry|June 18, 2005
Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practiceGyörgy Sölétormos, Axel Semjonow, Paul E C Sibley, et al.
Pageof 63

Showing results (411-420 of 629) with videos related to

Sort By:
Pageof 63
Dermatitis : Contact, Atopic, Occupational, Drug|February 1, 2023
The Association Between Fatigue and Adult Atopic Dermatitis: A Cross-Sectional StudyJacob P Thyssen, Lea K Nymand, Julia-Tatjana Maul, et al.
The Journal of Allergy and Clinical Immunology|January 8, 2011
TNF-like weak inducer of apoptosis (TWEAK) and TNF-α cooperate in the induction of keratinocyte apoptosisMaya Zimmermann, Andrea Koreck, Norbert Meyer, et al.
BJU International|November 22, 2017
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavirDominik Abt, Andrej Besse, Lenka Sedlarikova, et al.
Hepatology (Baltimore, Md.)|August 8, 2014
Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modelingJeremie Guedj, Yaron Rotman, Scott J Cotler, et al.
The Journal of Dermatological Treatment|February 12, 2016
Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndromeAstrid Sönnichsen, Ieva Saulite, Johanna Mangana, et al.
Future Oncology (London, England)|April 1, 2020
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancerHope S Rugo, Aditya Bardia, Sara M Tolaney, et al.
Cancer Research|March 16, 2011
Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancerNelofer Syed, Helen M Coley, Jalid Sehouli, et al.
Cancer Immunology, Immunotherapy : CII|April 14, 2006
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinomaYing Waeckerle-Men, Edith Uetz-von Allmen, Markus Fopp, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 30, 2025
PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [<sup>68</sup>Ga]Ga-PSMA-11, [<sup>68</sup>Ga]Ga-PSMA I&T, and [<sup>18</sup>F]PSMA-1007Caroline Burgard, Madita Frei, Arne Blickle, et al.
Clinical Chemistry|June 18, 2005
Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practiceGyörgy Sölétormos, Axel Semjonow, Paul E C Sibley, et al.
Pageof 63